Skip to main content

Mallinckrodt plc (MNK)

NYSE American Exchange Healthcare Drug Manufacturers - Specialty & GenericView data quality →
58.3Fair

ValueMarkers Composite Index

Top 70%#13,436 of 44,722

DCF data not available

Piotroski
0/9
Weak
Beneish
-
Altman
-
DCF Value
-
N/A
ROIC
-2.0%
Low
P/E
0.1
Value
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Mallinckrodt plc (MNK) — VMCI valuation read

MNK prints VMCI 58/100 inside the Healthcare sector, where the median sits at 50. The 8-point above-median delta is the cleanest single-number summary of Mallinckrodt plc's composite stance, and in the mid-cap bucket it places the share ahead of the typical peer on the five-pillar mix.

On MNK, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.

**Investor frame.** MNK trades at 22.0x earnings, 22% above the Healthcare median of 18.0x; that is the value line. ROIC of 18.0% sits 8.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of 3.1x is the binding constraint on the bear case; that is the risk line for Mallinckrodt plc on the trailing financials.

MNK rose 3.4% over the trailing 7 days, with a -6.0% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.